When would I be eligible for xofigo (radium-223)

Understanding Radium-223 (Xofigo) Eligibility

This is an excellent question, and it shows you're thinking strategically about treatment options. Let me explain the clinical context and eligibility criteria.

How Radium-223 Works

Radium-223 is an alpha-emitting radiopharmaceutical that targets bone metastases. It's particularly effective because it mimics calcium and concentrates in areas of bone with high turnover (where metastases typically cause increased bone activity). According to NCCN Guidelines and FDA approval data, it's designed to treat patients with:

• Castration-resistant prostate cancer (CRPC) with symptomatic bone metastases
• Disease that has progressed despite hormone therapy
• No visceral (organ) metastases

The Critical Issue for Your Situation

Radium-223 is FDA-approved specifically for castration-resistant prostate cancer. While your salivary duct carcinoma is AR-positive (androgen receptor-positive) and you're on LHRH therapy, SDC is a different cancer type than prostate cancer.

However—and this is important:

1. Off-label use is possible - Oncologists can use FDA-approved drugs for conditions outside their approved indication if there's clinical rationale. Some centers have explored radium-223 in AR+ cancers with bone metastases.

2. Your PSMA-PET may be relevant - If your scan shows PSMA-positive disease, this could potentially open doors to PSMA-targeted therapies (like lutetium-177 PSMA or other PSMA-directed treatments), which may be more directly applicable to your situation than radium-223.

3. Clinical trials matter - There may be trials specifically designed for AR+ salivary duct carcinoma with bone metastases that could include radium-223 or related approaches.

Questions to Ask Your Oncology Team

1. "Based on my PSMA-PET results, am I a candidate for PSMA-targeted therapies, and how would those compare to radium-223?"

2. "Have you considered radium-223 for my AR+ salivary duct carcinoma with bone metastases, and if so, what would be the clinical rationale?"

3. "Are there clinical trials available that specifically address bone metastases in AR+ salivary duct carcinoma?"

4. "What is the evidence for using radium-223 off-label in SDC, and would my insurance likely cover it?"

5. "What other bone-directed therapies should I know about (such as denosumab or zoledronic acid) that might complement my current treatment?"

Important Context

Your oncologist will need to weigh:

• The specific findings from your PSMA-PET
• Whether you meet criteria for radium-223 use (even off-label)
• Your overall disease burden and performance status
• Available clinical trial options
• Insurance coverage considerations

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

The eligibility question is nuanced for your specific cancer type, and your PSMA-PET results will likely be a key factor in determining which bone-directed therapies are most appropriate. Your care team is best positioned to evaluate whether radium-223 or alternative approaches make sense for your individual situation.